Clinical Trial Update: Deciphering Antitumour Response and Resistance With INtratumour Heterogeneity [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update examining how intratumour heterogeneity influences antitumor response and resistance in non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Snippet

Sponsor: University College, London | Conditions: Non-small Cell Lung Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING